Drug intelligence / Profile preview

Guardix-SP Plus

Development stage: Unknown
Lead developer: L&C Bio
Administration: Implant

Overview

Guardix-SP Plus is a thermo-sensitive, injectable anti-adhesion barrier designed to prevent post-operative adhesions following surgical procedures, particularly in spine surgery (such as laminectomy or discectomy). Developed by Genewel, it is a sol-gel formulation composed of Poloxamer 407 and Sodium Alginate. The product exists in a liquid (sol) state at room temperature, facilitating precise application to the surgical site, and undergoes a phase transition to a viscous gel at body temperature. This gel acts as a temporary physical barrier that separates internal tissues and organs during the critical healing period, thereby reducing the incidence of fibrous adhesion formation, which can lead to post-operative pain and complications.

Brand names: Guardix-SP PlusGuardix-SP
Other names: Guardix-SP

Beyond the preview

Go deeper on Guardix-SP Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guardix-SP Plus.

Explore the full profile